Skip to main content

Table 1 Sequences of oligonucleotide primers used in this study

From: Properties of resistant cells generated from lung cancer cell lines treated with EGFR inhibitors

Gene Forward Reverse
E-cadherin 5'-AGGAATTCTTGCTTTGCTAATTCTG 5'-CGAAGAAACAGCAAGAGCAGC
Vimentin 5'-GAGAACTTTGCCGTTGAAGC 5'-CTAACGGTGGATGTCCTTCG
Fibronectin 5'-GTT GTT ACC GTG GGC AAC TC 5'-CTG ACG GTC CCA CTT CTC TC
Occludin 5'-TTGGGACAGAGGCTATGG 5'-ACCCACTCTTCAACATTGGG
Snail 5'-TTCCAGCAGCCCAACGACCAG 5'-CGGACTCTTGGTGCTTGTGGA
Twist 5'-GGAGTCCGCAGTCTTACGAG 5'-TCTGGAGGACCTGGTAGAGG
Oct3/4 5'-CAGTGCCCGAAACCCACAC 5'-GGAGACCCAGCAGCCTCAAA
SOX2 5'-CAAGATGCACAACTCGGAGA 5'-GTTCATGTGCGCGTAACTGT
NANOG 5'-CAGAAGGCCTCAGCACCTAC 5'-ATTGTTCCAGGTCTGGTTGC
ID2 5'-GACCCGATGAGCCTGCTATAC 5'-AATAGTGGGATGCGAGTCCAG
BMI-1 5'-GATGCCACAACCATAATAGAA 5'-TCATTCACCTCCTCCTTAGAT
STAT3 5'-GGGTGGAGAAGGACATCAGCGGTAA 5'-GCCGACAATACTTTCCGAATGC